Stay updated on SL-701 Vaccine Clinical Trial for Recurrent Glioblastoma

Sign up to get notified when there's something new on the SL-701 Vaccine Clinical Trial for Recurrent Glioblastoma page.
Latest website image capture
Clouds background image

Latest updates to the SL-701 Vaccine Clinical Trial for Recurrent Glioblastoma page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the number of patients treated in a study evaluating the safety and efficacy of SL-701 as a treatment for recurrent glioblastoma multiforme.
    Difference
    0.1%
    Check dated 2024-06-06T14:49:57.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying that participants must be 18 years or older with histologically confirmed GBM or WHO Grade IV variants. Previously, no information was provided regarding participation criteria for collaborators and investigators.
    Difference
    51%
    Check dated 2024-05-22T21:30:53.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:53:12.000Z thumbnail image

Stay in the know with updates to SL-701 Vaccine Clinical Trial for Recurrent Glioblastoma

Enter your email address, and we'll notify you when there's something new on the SL-701 Vaccine Clinical Trial for Recurrent Glioblastoma page.